



Memorandum of Understanding
Between MAPS and SAEPT

September 22, 2006

1. MAPS welcomes the interest of Dr. Peter Gasser and the Swiss Association for Psycholytic Therapy (SAEPT) in conducting a pilot study into the use of LSD-assisted psychotherapy in subjects with anxiety due to life threatening diseases.
2. MAPS pledges to support the Swiss LSD /end-of-life anxiety study with a minimum of \$50,000, once the study is approved and ready to start. MAPS will also seek to raise an additional \$100,000, for the expected budget of roughly \$150,000.
3. MAPS will assist with the protocol design and approval process by making available the MAPS-initiated protocol and informed consent form for a study of MDMA-assisted psychotherapy in advanced-stage cancer patients with anxiety. MAPS will also assist with an updated LSD and psilocybin literature review and risk analysis, for submission to Swiss ethics committee and Health officials. These documents will be in English.
4. MAPS will also supply LSD, purchased in Switzerland, for use in the study.
5. MAPS will provide Case Report Forms and clinical monitoring of the study to facilitate acceptance of the data by FDA and the Swiss authorities.
6. MAPS will submit the protocol to the FDA for review and approval after the protocol has been approved by the Swiss ethics committee and Swissmedic. FDA will respond within 30 days of the submission of the protocol. If there are differences between what the FDA will accept and the design the SAEPT has gotten approved, MAPS is open to the idea of supporting a design in Switzerland that is different than what the FDA will accept.
7. SAEPT will submit the data gathered to the FDA as part of MAPS' Institutional New Drug application (IND) for LSD. SAEPT may submit the

Multidisciplinary Association for Psychedelic Studies

MAPS • Rick Doblin • 3 Francis Street • Belmont, MA. 02478-2218 •

617 484-8711, Fax: -8427 • www.maps.org • rick@maps.org



data anywhere else it chooses and may publish the data in any place or manner that it chooses. MAPS does not have any proprietary interest in the data but does want to be able to use the results of the study as part of our eventual submission to FDA of data seeking FDA approval to market LSD as a prescription medicine.

8. MAPS' long-term goals are to assist the SAEPT in conducting a large scale Phase III study with a similar design in Switzerland and perhaps throughout Europe and Israel, and to conduct a second large scale Phase III study in United States, with the intention of developing LSD into a prescription medicine in the US, Europe and Israel.

Rick Doblin, Ph.D
MAPS President

Dr.med.Peter Gasser
SAePT